Stocks to Buy. In this article, we are going to take a look at where Boston Scientific Corporation (NYSE:BSX) stands against ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...

Boston Scientific Corp. last week announced that it has closed on its acquisition of Irvine-based medical device maker ...

Boston Scientific (BSX) stock climbed 5% after a study showed its Watchman FLX device was superior to oral anti-coagulants in reducing bleeding risks following cardiac ablation.

For valuable insights into Boston Scientific's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our ...

Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.

for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented at ...

Co-founded company that makes sacral neuromodulation device to treat patients with overactive bladder conditions.   IN THE ...

Boston Scientific Corp.’s OPTION study demonstrated left atrial appendage closure with the Watchman Flx device reduced risk of stroke compared to management with direct oral anticoagulants or warfarin ...

Boston Scientific (BSX) announced the close of its acquisition of Axonics (AXNX). The purchase price of $71 cash per share represents an ...